Two Labs Blog

Two Labs Blog

Two Labs | MKO Global Partners

Find me on:

Recent Posts

Comparison of US and EU approaches to Oncology Management

Posted by Two Labs | MKO Global Partners on September 10, 2018

It was great meeting all of you who were able to stop by our booth in Glasgow! It was a great experience to present our findings to the industry innovators at ISPOR. The themes of early data evaluation and subsequent real word evaluations for management decision-making emerged throughout the day. We look forward to continuing our work in understanding trends and the feasibility of management strategies globally.


Key Learnings on Pathways of Care

Posted by Two Labs | MKO Global Partners on August 1, 2018

Oncology is a high cost and high management priority disease state for US payers, however, ability to control cost in this space is limited. MKO Global Partners, a Two Labs Company, conducted previous research that suggests oncology drugs are primarily managed to label and only occasionally are there policies in place to restrict or prefer certain agents.

1_mlHowever, new ways to control the cost of oncology care are emerging and are attracting attention. For example, pathways of care are considered a tool of growing relevance. Pathways, with or without risk sharing, are often mentioned as an oncology-specific cost containment tool, alongside other initiatives such as Oncology Care Models, changes in payment mechanisms for providers and, at least in part, value frameworks.

Despite the industry interest in pathways of care and other innovative oncology management tools, it is unclear what impact these new approaches will have on access at the local level. To explore this issue in-depth, MKO Global Partners organized a panel discussion with oncologists from different types of provider organizations.

Download White Paper

Learn about the three factors that emerged as key issues limiting payers' ability to manage oncology by downloading this paper.


Topics: MKO, Payers, ASCO

Targeted agents indicated for autoimmune diseases

Posted by Two Labs | MKO Global Partners on July 19, 2017

Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome. To further complicate the category, indications can be subdivided even further (e.g., by severity, juvenile vs. adult, etc.), increasing the complexity even more.


MKO Minute – Rise of Gene Therapy

Posted by Two Labs | MKO Global Partners on May 30, 2017

This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents. How will payers pay for these new gene therapies? Did Novartis set the price reference for Juno’s and Gilead/Kite’s CAR-T entrants?


Will lower cost therapies take share from legacy treatments?

Posted by Two Labs | MKO Global Partners on March 25, 2017

With recent disruptive pricing in the HCV market, will lower cost therapies take share from legacy treatments? Preview what payers forecast back in the second half of 2016 with our M Tracker data. Will their prediction become reality? Be on the lookout for the full report in the near future!


Management and Budget Impact

Posted by Two Labs | MKO Global Partners on March 13, 2017

With the evolution of payer management in different specialty classes, MKO has been tracking management priority and budget impact using our M Tracker. M Tracker has revealed a significant change in oncology and HCV management in the first half of 2017. Here is a preview of current payer opinions on specialty disease management, using our proprietary M Tracker data.


Click HERE to see the animation

MKO Minute – When Cures Become Commodities

Posted by Two Labs | MKO Global Partners on January 27, 2017

The price wars in Hepatitis C continues as both Gilead and AbbVie launch their respective products into a market with a diminishing number of new patient starts. Which of the companies’ pricing strategies will prevail?